438P Chemoimmunotherapy versus chemotherapy for extensive-stage small cell lung cancer: A retrospective real-world study of 904 patients
Year: 2026
Type: article
Study design: Observational Study
Abstract: Small cell lung cancer (SCLC) is an aggressive malignancy, with over 70% of patients diagnosed at the extensive stage (ES). Phase III studies have established chemoimmunotherapy (CIT) with PD-(L) 1- inhibitors as the new first-line standard for ES-SCLC based on significantly longer overall survival (OS) compared to platinum/etoposide (PE) chemotherapy (CHT). This study investigates the real-world efficacy of CIT compared with alternative first-line regimens in patients with ES-SCLC.
Source: ESMO Open
Authors: K. Dimitriou, S. Shi, A. Margineau, M. Blasi, F. Bozorgmehr, L. Klotz, F. Eichhorn, M. Schneider, R. Shah, H. Bischoff, F. Weykamp, A. Stenzinger, M. Thomas, P. Christopoulos
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7138186496
FWCI:
Cites:
Cited by:
Related to: